Low muscle mass impacts on morbidity and mortality in cirrhosis. The skeletal-muscle index (SMI) is a well-validated tool to diagnose muscle wasting, but requires specialized radiologic software and expertise. Thus, we compared different Computed tomography (CT)-based evaluation methods for muscle wasting and their prognostic value in cirrhosis.
| INTRODUC TI ON
Sarcopenia is highly prevalent in advanced chronic liver disease (ACLD) with reported prevalence rates ranging between 22% and 70%. 1, 2 Once sarcopenia develops, prognosis is significantly impaired and patients are at increased risk for liver-related morbidity and mortality. 1, [3] [4] [5] [6] Based on these findings, the 'MELD-Sarcopenia'-Score has been developed and has shown a higher accuracy in predicting mortality within 3 months compared to MELD alone. 7 However, a recent study did not confirm an increase in the prognostic value of sarcopenia in addition to MELD. 4 Computed tomography (CT)-based methods represent the gold standard for diagnosing sarcopenia, 8 with skeletal-muscle index (SMI) being the most commonly used parameter. SMI is calculated from the cross-sectional area of abdominal skeletal muscles at the third lumbar vertebrae, normalized by body height. 8, 9 Although the SMI was reported to be an independent risk factor for mortality, 5, 10 it has two main limitations: firstly, a specific software is needed to measure the cross-sectional area of abdominal skeletal muscle, and secondly, this measurement requires the expertise of an experienced radiologist.
Hence, several studies have used different CT-based methods to investigate the prognostic value of sarcopenia in cirrhosis. The total psoas muscle area and the corresponding psoas muscle-index have been widely studied 1 but also require volumetry, and thus, specific software. Total psoas muscle volume (TPV) predicted post-operative complications following hepatic surgery. 11 More recently, the paraspinal muscle index (PSMI) has been shown to predict mortality in a large cohort of patients with cirrhosis. 12 Transversal psoas muscle thickness (TPMT) is an easy-to-use and readily available parameter in clinical practice since it is just based on the psoas diameter. Importantly, the TPMT was an independent risk factor for mortality on top of MELD or MELD-Na. 3 The detrimental impact of sarcopenia on survival has subsequently been confirmed by several studies. 4, 6, 7, 13, 14 Thus, strategies to improve muscle wasting are now widely accepted as important treatment goals in ACLD patients, 9, 15, 16 however standardized and clinically feasible assessment of muscle mass is still lacking and randomized controlled trials on specific interventions are rare. Intramuscular testosterone injection has been shown to increase muscle mass in male patients with ACLD, however, no beneficial effects on liver-related outcomes were observed. 17 Therefore, we aimed to compare four different CT-based methods for diagnosing low muscle mass (SMI, TPMT, TPV and PSMI) in regard to their prognostic value for liver-related mortality.
| ME THODS

| Patients
Patients from a prospective registry undergoing a CT scan within ±200 days of inclusion were analysed ( Figure 1 ). Inclusion criteria were: available CT scan, diagnosis of cirrhosis (based on clinical, laboratory or radiological findings) 18 and available information on standard laboratory parameters. Exclusion criteria were: missing CT scan and/or impossibility to calculate SMI and TPMT, missing laboratory parameters or unavailability of clinical follow-up and hepatocellular carcinoma at baseline. Inclusion of patients started in 2012, liver-related complications (ie decompensation) were recorded and patients were followed until transplantation, death or date of last clinical visit. Survival time was assessed from the time of the CT scan until censoring/the first event, as defined above. During this study, patients were treated according to the guidelines in effect during the time. [18] [19] [20] Out of 338 patients included in the prospective database 219 were excluded because of missing CT scans within ±200 days of study inclusion. Further 10 patients were excluded due impossible calculations of SMI and TPMT (incomplete abdominal CT scan with missing third lumbar vertebrae layer).
| Image analysis
All measurements were obtained on axial CT scans of the abdomen performed on a multidetector CT scanner with a patient size-adapted tube voltage (80-120 kVp) an active tube current modulation. Seventy to one hundred and twenty millilitres (depending on the body weight) of iodinated contrast agents (300-400 mg/mL Iodine concentration) was given intravenously at a peripheral vein at a flow rate of 4-5 mL/s, followed by a saline flush of 20 mL using a power injector. All imaging data were acquired on transverse venous phase images using a soft tissue kernel (B30F), with a section thickness of 3 mm and a reconstruction interval of 2 mm.
The SMI, TPMT, PSMI and psoas volume were calculated in all patients at the level of the third lumbar vertebrae (L3) using OsiriX medical imaging software for iOs (Pixmeo, Version 7.5) and syngo.via software (Siemens Healthcare GmbH, Version VB30).
Total psoas volume (TPV) of the entire psoas muscle was calculated in 79 patients using syngo.via software (Siemens Healthcare
Key points
• Low muscle mass is a risk factor for early hepatic decompensation and death in patients with cirrhosis. Computed tomography (CT) based methods are the gold standard to diagnose low muscle mass.
• In this study we compared four different CT-based methods for the diagnosis of low muscle mass and found the transversal psoas muscle thickness (TPMT) as an independent risk factor for mortality.
• The TPMT is easy to calculate, does not require specific radiologic software and could therefore emerge as a feasible tool for the clinical hepatologist to diagnose low muscle mass.
GmbH, Version VB30). Thirty patients had only upper abdominal CT scans and measurement of TPV was therefore not possible.
Transverse venous phase images of the abdomen were loaded.
As previously described, 21 An independent reader, instructed by a senior board-certified radiologist analysed all variables. In case of SMI and TPMT a second independent reader, instructed by a senior board-certified radiologist additionally analysed the variables, and mean values of both measurements where then taken into account for statistical analysis.
Interrater-variability kappa statistics was 0.70 for TPMT-L3 and 0.75 for SMI, indicating per definition 'substantial agreement'.
| Definition of cut-offs for low mucle mass
Low muscle mass was defined according to established SMI cut-offs: 
| Ethics
| RE SULTS
| Patient population
One hundred and nine patients were included in this study. Low muscle mass as defined using SMI was present in 69 patients (63.3%; Table 1 ). The main patient characteristics stratified according to presence or absence of low muscle mass are summarized in Table 1 . Thirty patients (27.5%) died during follow-up, significantly more among those with low muscle mass (66.7% vs 33.3%, P = .049).
Reasons of death were: Acute on chronic liver failure 19 (63.3%) [decompensated cirrhosis and multi-organ failure n = 12 (63%), sepsis/ infection n = 6 (32%), haemorrhagic shock n = 1 (5%)], hepatocellular carcinoma n = 5 (16.6%), unknown n = 4 (13.4%) and cardiac decompensation 2 (6.7%). Twenty (18.4%) patients were transplanted during follow-up.
| Establishing low muscle mass cut-offs in cirrhosis for TPMT, PSMI and TPV
Using SMI as the reference method to define muscle wasting, diag- 
| Low muscle mass-as defined using SMI vs TPMT vs PSMI vs TPV to predict mortality
To compare the predictive value of each CT-based definition method we performed competing risks analyses for each definition (Figure 2A -D). Univariate competing risks analyses found a significant risk for mortality when patients were stratified according to SMI-(aSHR: 2.52, 95% CI: 1.03-6.21, P = .043, Figure 2A ), TPMT-(aSHR: 3.87, 95% CI: 1.4-8.09, P = .007, Figure 2B ) and PSMI-(aSHR: 2.7, 95% CI: 1.17-6.23, P = .02, Figure 2C ) derived low muscle mass cut-offs (Table S1 ).
In contrast TPV-defined low muscle mass (aSHR: 1.96, 95% CI: 0.73-5.3, P = .18, Figure 2D ) was not associated with an increased risk for mortality.
Subsequently, we evaluated the independent predictive value of SMI-, TPMT-and PSMI-defined low muscle mass using multivariate competing risks models (Model-1: SMI, Model-2: TPMT; Model 3:
PSMI; Table S1 ).
Interestingly, only TPMT (aSHR: 2.82, 95% CI: 1.20-6.67, P = .018) was independently associated with mortality in our competing risks model, while SMI (aSHR: 1.93, 95% CI: 0.72-5.16, P = . 19 ) and PSMI (aSHR: 1.93, 95% CI: 0.79-4.75, P = .15) were not.
| Defining cut-offs for muscle mass parameters that correlate with survival
Using mortality as the endpoint, cut-offs were calculated based on AUROC analysis and Youden index. The SMI-AUC was 0.63 
| Prediction of mortality by muscle mass parameters (survival cut-offs)
Univariate competing risks analysis showed a significantly higher risk for mortality when SMI-(aSHR: 3.84, 95% CI: 1.9-7.78, P < .001; Figure 3A ), TPMT-(aSHR: 19, 95% CI: 2.62-138, P = .004; Figure 3B ), PSMI-(aSHR: 3.67, 95% CI: 1.59-8.48, P = .002, Figure 3C ) but not TPV-(aSHR:1.74, 95% CI: 0.73-4.17, P = .21) derived mortality cutoffs were used.
We then performed multivariate competing risks analysis and found SMI-(aSHR: 2.96, 95% CI: 1.41-6.21, P = .004, Table 2 ) TPMT-(aSHR: 16.18, 95% CI: 2.15-122.04, P = .004, Table 2 ) and PSMI-(aSHR: 2.64, 95% CI: 1.08-6.43, P = .03, Table 2 ) derived mortality cut-offs independently associated with mortality.
| D ISCUSS I ON
Giving the detrimental effects of sarcopenia on liver-related outcomes and mortality in patients with ACLD, reversing muscle-loss represents a management priority in these patients. 9, 22 Sarcopenia in ACLD is multifactorial and the pathophysiology include proteinmalnutrition, increased proteolysis from skeletal muscles, accelerated starvation response, physical inactivity or humoral factors such as upregulation of myostatin as a result of hyperammonaemia or hypotestosteronism. 8, 9, [22] [23] [24] Nutritional supplementation with branched chain amino acids (BCAAs) has been shown to improve liver-related outcomes 25 and muscle mass. 26 Furthermore exercise interventions have resulted in improvement of cardiorespiratory endurance, 27,28 muscle mass 27 and a reduction in hepatic venous pressure gradient. 29, 30 More recently intramuscular testosterone supplementation has been shown to improve muscle mass, although no effect on liver-related outcomes was observed. 17 Furthermore transjugular intrahepatic portosystemic shunt (TIPS)-implantation has been shown to potentially reverse sarcopenia 31 refractory ascites 32 or variceal bleeding. 33 Nevertheless, the only available data that show an improved survival when overcoming sarcopenia come from trials investigating patients before and after TIPS. 31, 34 While persistence of sarcopenia after TIPS was associated with an impaired outcome, it is unclear whether this is of associative (since patients with sarcopenia pre-TIPS typically present with more severe liver disease) or causative reasons. 31, 34, 35 A variety of methods to measure thickness or volume of the psoas major muscle on CT scans have been published 1, 8 and a recent study 36 that compared the psoas muscle area (PMA) to the SMI showed that PMA outperformed SMI in the prediction of 1-year mortality after liver transplantation.
This is the first study comparing four CT-based methods for the diagnosis of low muscle mass, in regard to their diagnostic and prognostic value in patients with ACLD.
Most studies evaluating muscle mass in cirrhosis have used the SMI as the reference method and used SMI cut-offs derived from an oncology-cohort published by Prado et al. 21 Using SMI, several studies 4,5,7,10,37,38 have demonstrated that low muscle mass is associated with impaired survival in patients with cirrhosis. More recently, one study investigated cirrhosis-specific SMI cut-offs 37 and proposed new SMI-derived cut-offs for the diagnosis of sarcopenia in ACLD: for men 50 cm 2 /m 2 and for women: 30 cm 2 /m 2 ), and recently the European Association for the Study of the Liver (EASL) suggested cut-offs of <50/ <39 cm 2 . 39 In our cohort applying the EASL proposed cut-offs would have reclassified five patients, nevertheless the predictive value for mortality remained the same ( Figure S3 ). Using SMI as the reference method, 21 the prevalence of low muscle mass was as high as 63%
in our ACLD cohort. Similarly high rates of muscle wasting in cirrhosis have previously been reported 5, 10 in other studies and suggested that sarcopenia increases the risk for decompensation and death. 3, 5, 10 In a recent review Kim et al 1 reported on 10 studies using SMI, eight studies using total psoas muscle area and two studies using In our study, we could show that low muscle mass in ACLD can be identified using different CT-based diagnostic algorithms, thereby we found a high prevalence of low muscle mass in up to two thirds of ACLD patients. Importantly, lower mortality-derived muscle mass cut-offs for SMI and similar ones for TPMT and PSMI were found to already be associated with increased mortality in our ACLD cohort. Most strikingly, the TPMT was the only independent predictor of mortality, irrespective of the chosen cut-off (muscle mass-or mortality-derived), on multivariate analyses and therefore even outperforming the SMI that requires much more infrastructure and resources to obtain. Whether measuring the TPMT at the level of the umbilicus or the third lumbar vertebrae as the method of choice is debated. Recently, Praktiknjo et al 34, 41 described very heterogenous locations of the umbilicus in their study (L4 in 70%, L5 in 20% and L3 in 10%), which may add substantial variability to the measurement of TPMT that is related to the measurement position, rather than psoas muscle itself. We also measured TPMT at the umbilicus level and also observed considerable heterogeneity regarding the relation between the axial skeleton and the umbilicus and were not able to measure TPMT-umbilical in 11 patients because of missing umbilicus on the CT scan (mostly because of CT scans limited to the splenoportal axis and massive ascites). Nevertheless we found a good prognostic capability of gender specific, mortality-derived TPMT-umbilical cut-offs in the 98 remaining patients ( Figure S2 ).Thus, we propose to use gender-specific mortality-derived TPMT-L3 cut-offs for men and women at <12 mm/m and at <8 mm/m respectively, to identify low muscle mass already at a level that impacts on mortality in ACLD.
The to the distal origin (L5-S1) 42, 43 the diameter increases. Therefore, TPMT values are lower when measuring at more proximal levels.
Nevertheless, the median TPMT at the umbilical level in our cohort was 17.7 mm/m (14.5-20.5) , and therefore quite comparable to Durand et al. 3 Interestingly we did not see a difference in the prevalence of presence of hepatic encephalopathy (HE) between patients with "normal" vs. low muscle-mass, even though hyperammonemia can lead to muscle wasting. 22 This could be explained by the fact that the presence or absence of HE was classified according to clinical presentation of the patient, not ammonia levels.
Furthermore ammonia levels do not correlate with the severity of hepatic encephalopathy. [44] [45] [46] Another possible explanation might be the link between muscle wasting and already minimal hepatic encephalopathy (MHE) as suggested by a recent study. 47 In conclusion, low muscle mass is highly prevalent in cirrhosis.
The TPMT is a valuable tool to diagnose muscle wasting and to identify patients at risk for increased mortality. Ultimately, timely diagnosis of low muscle mass at gender-specific TPMT cut-offs might accelerate the initiation of specific treatment strategies against muscle wasting in ACLD patients.
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